VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

Shilpa Gupta, MD
Published: Monday, Aug 07, 2017



Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

There is a lot of interest in adjuvant therapy in kidney cancer, Gupta says. Trials with immunotherapy are being compared with placebo, but Gupta says that these agents should probably be compared with sunitinib (Sutent), if it gains FDA approval.

Additionally, Gupta says that patients with non-clear cell kidney cancer should be included in these adjuvant trials as well.
 


Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

There is a lot of interest in adjuvant therapy in kidney cancer, Gupta says. Trials with immunotherapy are being compared with placebo, but Gupta says that these agents should probably be compared with sunitinib (Sutent), if it gains FDA approval.

Additionally, Gupta says that patients with non-clear cell kidney cancer should be included in these adjuvant trials as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x